Efficacy and Safety of Colesevelam in Pediatric Patients With Genetic High Cholesterol
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the lipid-lowering effect and safety of colesevelam therapy
administered to heterozygous familial pediatric patients 10 through 17 years of age who are
on a stable dose of a pediatric-approved statin monotherapy (atorvastatin, lovastatin,
simvastatin or pravastatin), or who are treatment naive to lipid-lowering therapy.